Physician
Gosai, Jayesh
Gosai, Jayesh was paid $404K by Medicaid between Aug 2020 and Nov 2024, across 35 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 20% of everything it billed.
33Billing provider infoGOSAI, JAYESH
RICES LANDING, PA 15357
RICES LANDING, PA 15357
33aNPI1841253937assigned 04/10/2006
33bProvider typeInternal Medicine Physician
28Total paid$404K
24GClaims9,862
24DCodes billed35
24AFirst – last monthAug 2020 – Nov 2024
Compared with peers
Next to other Internal Medicine Physician providers in Pennsylvania
Rank by total paid#66 of 1,726
Median peer was paid$6K
This provider vs. median62×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,729 | $88K | |
| 2021 | 4,839 | $218K | |
| 2022 | 1,448 | $62K | |
| 2023 | 640 | $26K | |
| 2024incomplete | 206 | $10K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 1,705 | 1,340 | $82K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 19% | 2,225 | 2,019 | $77K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 13% | 757 | 745 | $51K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 9.9% | 1,020 | 1,009 | $40K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.0% | 1,110 | 952 | $36K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 7.8% | 339 | 323 | $31K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 5.2% | 73 | 69 | $21K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 4.1% | 50 | 49 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 212 | 186 | $8K |
| 87631 | 1.3% | 36 | 35 | $5K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 176 | 124 | $5K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 74 | 73 | $4K |
23 more codes
| 87275 | <1% | 266 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 65 | $3K |
| 80053 | Comprehensive metabolic panel | <1% | 253 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 69 | $2K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 57 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 102 | $2K |
| 36000 | <1% | 236 | $2K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 265 | $2K |
| 87428 | <1% | 26 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 55 | $1K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 25 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 55 | $693.28 |
| 80061 | Lipid panel | <1% | 40 | $585.20 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 38 | $448.18 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 15 | $419.20 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 57 | $392.70 |
| 36415 | Collection of venous blood by venipuncture | <1% | 15 | $26.25 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 233 | $8.71 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 19 | $5.10 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19 | $1.80 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 41 | $0.35 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 69 | $0.02 |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 65 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.